EMR — Emerson Electric Co.

Sell-side sentiment is solidly positive: 23 buys vs. 16 holds and 3 sells, a consensus Buy rating, and a wave of target increases after the Aug 4, 2026 print (Evercore ISI $185 to $190, Bernstein $169 to $186, Citigroup to $182), with the consensus target at $164.67 (recent average $165.20). The tape, however, has cooled: as of 2026-09-13 EMR is -7.09% over one month and -0.41% over one week, sitting 1.54% below its 20-day SMA even while still 6.28% above its 200-day. That divergence says investors sold the beat-and-raise into strength after the run toward the $166.35 52-week high, so the near-term posture is balanced rather than euphoric.

Revenue growth is re-accelerating modestly, not decelerating: FQ3 FY26 (June 2026) sales of $4.873B rose 7.0% YoY, versus +2.9% in FQ2 FY26 ($4.562B), +4.1% in FQ1 FY26 ($4.346B) and +5.1% in FQ4 FY25 ($4.855B); management also reported underlying order growth of +7%, which supports the forward view. Margins are the cleaner and more important story: operating margin hit 20.5% in FQ3 FY26 (operating income $1,001M) versus 19.9% in FQ3 FY25, 18.2% in FQ3 FY24 and a charge-depressed 8.9% in FQ1 FY24 - a genuine ~250bp multi-year expansion, not a one-quarter blip. GAAP EPS is noisy because of one-offs (FQ1 FY24 $0.248 and FQ3 FY24 $0.572 versus FQ4 FY24 $1.73 on a large gain), so the FQ3 FY26 split of $1.28 GAAP / $1.71 adjusted is the better guide, and the $718M of net income was the highest clean quarter in the three-year window. Cash flow is inflecting hardest: TTM free cash flow of $3.46B (FQ3 FY26 alone $1.322B, a window record) is up roughly 26% from $2.74B a year earlier, while long-term debt fell from $8.319B (Sep 2025) to $7.526B (Jun 2026). Net: mid-single-digit growth with real margin expansion and improving cash conversion - an inflection, but a modest one, not a hyper-growth story.

Expensive on trailing and asset-based measures, closer to fair on forward adjusted earnings. As of 2026-09-13 the trailing P/E is 33.2x against a 5-year average of 26.0x, price/sales is 4.57x against a 3.77x 5-year average, price/book is 4.17x against an 11.3% ROE and 7.3% ROIC, and EV/EBITDA is 18.9x. But TTM GAAP EPS of $4.61 is depressed by acquisition amortization and prior restructuring charges; on the FY2027 consensus adjusted EPS of $6.56 the forward P/E is just 23.2x - below the 5-year average trailing multiple and well below the ~25x implied by the $164.67 consensus target. Free cash flow yield is about 4.1% ($3.46B TTM / $85.2B cap) and dividend yield is 1.361%. The -19.35 PEG ratio is a mathematical artifact of a negative growth input, not a signal. Verdict: you are paying a premium-quality multiple for mid-single-digit growth - not a bargain, not egregious, and the whole bull case rests on margins holding above 20%.

At $152.16 on 2026-09-13 the market pays roughly 23x FY2027E adjusted EPS for a business compounding adjusted EPS in the mid-single digits - implied PEG near 3.5 - so the multiple already assumes continued margin expansion and no order-cycle stumble. The Aug 4 beat-and-raise was real (adjusted EPS $1.71 vs. $1.67, guidance raised to the upper end of the range), yet the stock fell 7.1% over the following month, which tells you the good news was largely in the price after the run to $166.35. The asymmetry now: if November's FY27 guidance confirms 6-8% underlying growth with 20%+ margins, 23-25x is defensible and $164-175 is reachable; if orders decelerate or Europe, China and FX subtract more than expected, the stock compresses to ~20x forward (about $131) without much imagination. One flag worth watching: the FY2027 consensus revenue estimate of $18.88B implies essentially flat sales versus the FY26 run-rate of roughly $18.7B, which conflicts with management's own order momentum - either the Street is sandbagging ahead of guidance, or it is modeling a drag (FX, divestitures) management has not highlighted.

As of 2026-09-13, RSI(14) was 48.89 - dead neutral, neither oversold nor overbought - with the price 1.54% below its 20-day SMA (roughly $154.5), 1.39% above its 50-day (roughly $150.1) and 6.28% above its 200-day (roughly $143.2). That is textbook consolidation inside an intact uptrend: the 6-month return is +15.09% and the 3-month is +6.37%, while the 1-month is -7.09%, so momentum has cooled rather than broken. Timing implication: there is no oversold entry and no confirmed breakout - the stock is range-bound between roughly $143 (200-day) and $166 (52-week high). A dip into the low $140s offers materially better risk/reward than buying at $152, while a decisive reclaim of the 20-day on volume would confirm the uptrend is resuming.

• Multi-year LNG, power generation and alternative-energy capital expenditure cycles, plus nearshoring/reshoring of process manufacturing, are the structural demand engine behind the 7% underlying order growth reported in FQ3 FY26.
• Interest rates remain the key swing factor for broader industrial capex - high rates temper general manufacturing investment, though Emerson's exposure to mission-critical infrastructure has insulated it better than cyclical peers so far.
• Regional softness in Europe and China, plus foreign-exchange translation drag on international revenue, are persistent second-order headwinds management continues to flag.
• Middle East geopolitical disruption creates fluid project timing even as baseline rebuild and energy-security spending offsets near-term delays (e.g., the BP Shah Deniz and Equinor awards).
• Sector rotation and the market's willingness to pay a software/automation premium for industrial franchises directly drives Emerson's multiple, which at 18.9x EV/EBITDA sits above the broad industrial average and is therefore more sensitive to sentiment shifts than to earnings revisions.

• Q4 and full-year FY2026 results plus initial FY2027 guidance in early-to-mid November 2026 - the single biggest swing event, particularly the direction of the FY27 revenue and EPS reset versus the current $18.88B / $6.56 consensus.
• Order backlog conversion and continuation of the +7% underlying order growth trend, which would validate the re-acceleration from +2.9% (FQ2 FY26) to +7.0% (FQ3 FY26) revenue growth.
• Execution of the ~$2.2B FY2026 capital return plan ($1B buybacks plus ~$1.2B dividends, with the $0.555 quarterly dividend paid Sept 10, 2026) and any signal of an accelerated repurchase pace.
• Continued Software & Systems outperformance and industrial-AI product traction (AMS machine health, PACEdge upgrades) plus announced project wins (BP Shah Deniz, Equinor instrumentation) converting into revenue.
• Sell-side target revisions continuing upward after the Evercore/Bernstein/Citi raises, or conversely a downward reset if November guidance disappoints - with the current target range an unusually wide $135 to $186, the reaction function is asymmetric.

• Valuation risk is the headline: 33.2x trailing GAAP earnings, 18.9x EV/EBITDA and 4.17x book against a 7.3% trailing ROIC leaves little cushion, and a simple re-rating to the 5-year average 26x trailing P/E on depressed GAAP EPS implies meaningful downside if sentiment on industrial multiples cools.
• Cyclical exposure to process-industry capex (energy, chemicals, refining) means the current +7% order growth is a peak-ish comparison base; an energy or chemicals capital-spending pause would hit orders with little warning.
• Liquidity is thinner than typical for a mega-cap industrial: current ratio of 0.896 and quick ratio of 0.663, with total debt of roughly $13.8B (0.677x equity) against only $2.18B of cash, though $3.46B of TTM free cash flow mitigates the practical risk.
• Earnings-quality gap: FQ3 FY26 GAAP EPS of $1.28 versus $1.71 adjusted means roughly $0.43/share of adjustments in a single quarter; if those amortization and one-off items are less benign than assumed, the cheap-looking 23x forward P/E is partly an artifact.
• Macro and regional drag - European and Chinese softness, FX translation, and Middle East disruption - could quietly erode the top line even while margins hold, and the flat FY2027 consensus revenue estimate suggests the Street already suspects this.

A genuinely good business at a full price. Emerson is delivering what you want to see - 7% underlying orders, operating margin up ~250bp from the FY24 base to 20.5%, record quarterly free cash flow of $1.322B, and long-term debt down to $7.526B - but as of 2026-09-13 at $152.16 the stock trades at 23.2x forward adjusted EPS and 18.9x EV/EBITDA for mid-single-digit growth, and my own fair value of $153 leaves essentially no margin of safety. I would not buy at this price: own it for the franchise quality, but wait for either a pullback into the $135-145 zone (which is also the low end of the analyst range and near the 200-day average) or a November FY27 guidance that forces estimates materially higher before adding.

Primary method is a forward P/E on adjusted earnings: 23.3x applied to the FY2027 consensus adjusted EPS of $6.56 gives $153.0, where the multiple is set at roughly a 10% discount to the 5-year average trailing P/E of 26.0x to reflect mid-single-digit adjusted EPS growth (~6-7%), a 7.3% trailing GAAP ROIC and a 0.896 current ratio, while still crediting the 20.5% operating margin, +7% underlying orders and 4.1% free cash flow yield. Cross-check: about 18.5x on roughly $5.1B of EBITDA less approximately $11.6B of net debt (total debt ~$13.8B less $2.18B cash) yields ~$149, and for reference 20x forward EPS ($131) is the bear floor while 25x ($164) is where the sell-side consensus target sits.